ArticlePharmaceutical research2023
Dissolution Profiles of Poorly Soluble Drug Salts in Bicarbonate Buffer.
Article in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 18 citations in OpenAlex.
- In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.The AAPS journal · 2026Article
- Dissolution Profile of Tosufloxacin Tosylate in Biorelevant Bicarbonate Buffer Containing Sodium Chloride: Precipitation of Hemi-hydrochloride Salt at the Particle Surface.Pharmaceutical research · 2025Article
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio.Pharmaceutical research · 2025Article
- Effect of bicarbonate buffer on artificial membrane permeation of drugs.ADMET & DMPK · 2025Article
- Dissolution Profiles of Immediate Release Products of Various Drugs in Biorelevant Bicarbonate Buffer: Comparison with Compendial Phosphate Buffer.Pharmaceutical research · 2024Article
- Solubility vs Dissolution in Physiological Bicarbonate Buffer.Pharmaceutical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the present study was to investigate the effect of buffer species on the dissolution profiles of poorly soluble drug salts, focusing on bicarbonate buffer (BCB).
methodsPioglitazone HCl (PIO HCl) and dantrolene sodium (DNT Na) were used as model drugs. Non-sink dissolution tests were performed using phosphate buffer (PB) and BCB (pH 6.5, buffer capacity: 4.4 mM/pH, ionic strength: 0.14 M, with/ without bile micelles). The pH value of BCB was maintained using a floating lid that avoided the loss of CO
resultsThe dissolution of PIO HCl was slower in BCB than in PB, whereas that of DNT Na was faster in BCB than in PB. The same trend was observed in the presence of bile micelles. Free-form precipitation on the surface of salt particles was observed early in their dissolution in both BCB and PB. However, the surface textures in BCB and PB were different. The bulk-phase precipitation of PIO was little affected by buffer species, whereas that of DNT was affected, but oppositely to the dissolution profile.
conclusionThe dissolution profiles of PIO HCl and DNT Na in BCB were markedly different from those in PB. Free-form precipitation on the particle surface, rather than in the bulk phase, was affected by buffer species in the dissolution test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.